Testosterone for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Elias, Alby ^a   Kumar, A ^b  

^a Jubilee Mission Medical College   (India)

^b NONE

Author keywords

Antipsychotic agents *therapeutic use ; Chemotherapy, adjuvant; Dehydroepiandrosterone *therapeutic use ; Humans; Randomized controlled trials as topic; Schizophrenia *drug therapy ; Testosterone *therapeutic use

Indexed keywords

ESTROGEN DERIVATIVE; NEUROLEPTIC AGENT; PRASTERONE; SEX HORMONE; TESTOSTERONE; TESTOSTERONE DERIVATIVE;

AKATHISIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; QUALITY OF LIFE; RANDOMIZATION; RATING SCALE; REVIEW; SAINT HANS RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 37849037372     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006197.pub2     Document Type: Review

References (60)

1. Nachshoni 2005 {published data only} *Nachshoni T, Ebert T, Abramovitch Y, Asael-Amir MM, Weizman A, Kotler M, Strous RD. The effect of DHEA administration on extrapyramidal symptoms in schizophrenia: a randomized double blind placebo controlled trial. Journal of the European College of Neuropsychopharmacology 2005;15(Suppl. 2):S135.
2. Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophrenia Research 2005;79(2-3):251-6. [MEDLINE: 16126372].
3. Ritsner 2006 {published data only} Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychopharmacology 2006;26(5):495-9.
4. Strous 2002 {published data only} Strous R, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Use of dehydro - epiandrosterone in the management of negative symptoms of schizophrenia. Journal of the European College of Neuropsychopharmacology 2002;12(Suppl 3):S286.
5. Strous RD, Maayan R, Kotler M, Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clinical Neuropharmacology 2005;28(6):265-9. [MEDLINE: 16340380].
6. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Archives of General Psychiatry 2003;60:133-41. [MEDLINE: 12578430].
7. Brambilla 1979 Brambilla F, Scarone S, Ponzano M, Maffei C, Nobile P, Rovere C, Guastalla A. Catecholaminergic drugs in chronic schizophrenia. Neuropsychobiology 1979;5(4):185-200. [MEDLINE: 375121].
8. Cotes 1978 Cotes PM, Crow TJ, Johnstone EC, Bartlett W, Bourne RC. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychological Medicine 1978;8(4):657- 65. [MEDLINE: 364517].
9. Ishigooka 1991 Ishigooka J, Wakatabe H, Murasaki M, Miura S. Phase I study of risperidone, a new antipsychotic drug of benzisoxazol derivative. Rinsho Hyoka (Clinical Evaluation) 1991;19(1):93-163.
10. Kinon 2006 Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006;31(5):577-88. [MEDLINE: 16488084].
11. Knegtering 2004 Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, Van Den Bosch RJ. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology 2004;24(1):56-61.
12. Ko 2006 Ko YH, Joe SH, Jung SW, Lee CH, Jung HG. Beneficial effect of short-term testosterone adjuvant treatment for negative symptoms of male schizophrenia. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S376.
13. Kulkarni 2002 Kulkarni J, de Castella A, Downey M, Taffe J, Fitzgerald P. Estrogen-a useful adjunct in the treatment of men with schizophrenia?. Schizophrenia Research 2002;53(3 Suppl 1):10.
14. Kulkarni 2005 Kulkarni J, de Castella A. Estrogen treatment in women with schizophrenia. Schizophrenia Bulletin 2005;31:512-13.
15. Poyurovsky 2003 Poyurovsky M, Maayan R, Gil-Ad I, Weizman A, Weizman R. Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003.
16. Rinieris 1988 Rinieris P, Hatzimanolis J, Markianos M, Stefanis C. Effects of 4 weeks treatment with chlorpromazine and-or trihexyphenidyl on the pituitary gonadal axis in male paranoid schizophrenics. European Archives of Psychiatry and Neurological Sciences 1988;237(4):189-93.
17. Sackler 1951 Sackler MD, Sackler RR, Sackler AM, van Ophujsen JHW. Sex steroid therapy in psychiatric disorders: the therapeutic effect of testosterone and estradiol on hospitalized psychotics; clinical findings. Acta Psychiatrica et Neurologica Scandinavica 1951;26:415-37.
18. Shen 2001 Shen G, Han J, Song L. A comparative the results of serum testosterone levels in different age-group of male schizophrenics. Sichuan Mental Health 2001;14(4):205-6.
19. Song 2002 Song J, Guo J, Shen G. A comparative study of sexual hormones in patients with some mental disorders. Journal of Clinical Psychological Medicine 2002;12(3):137-9.
20. Strous 2006 Strous RD, Stryjer R, Maayan R, Gal G, Eisner D, Weizman A. Amelioration of symptomatology, Parkinsonism and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in schizophrenia. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S408.
21. von Bahr 1991 von Bahr C, Wiesel FA, Movin G, Eneroth P, Jansson P, Nilsson L, Ogenstad S. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology 1991;103(4):443-8. [MEDLINE: 91288734].
22. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
23. Andreasen 1985 Andreasen NC. Negative syndrome in schizophrenia-strategies for long term management. Advances in Biochemistry and Psychopharmacology 1985;40:1-7.
24. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
25. Boissel 1999 Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buysey M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indises. 3. Comparison of indises and their use. Therapie 1999;54(4):405-11.
26. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
27. Chouinard 1980 Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Science 1980;7:233.
28. Crow 1980 Crow TJ. Positive and Negative Symptoms and the role of dopamine. British Journal of Psychiatry 1980;137:183-6.
29. Deeks 2000 Deeks J. Issues in the selection of meta-analysis for binary data. Abstracts in 8th Cochrane Colloquium , 2000, October 25-28, Cape Town, South Africa. 2000.
30. Dilling 2000 Dilling H, Mombour W, Schmidt MH. WHO Internatioanale Klassifikation Psychischer Storungen ICD-10 Kapitel V(F) Klinisch-diagnostische Lietlinien. Geneva: Verlag Hans Huber, 2000.
31. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
32. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
33. Duggan 2002 Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia (Cochrane review). Cochrane Database of Systematic Reviews 2002, Issue 3.
34. Gerlach 1993 Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Pscyhiat Scand 1993;87(4):244-52.
35. Goyal 2004 Goyal 2003, Sagar R, Ammini AC, Khurana ML, Alias AG. Negative correlation between negtaive symtoms of schizophrenia and testosterone levels. Annals of the New York Academy of Science 2004;1032:291-4.
36. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
37. Guy 1976 Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
38. Harris 2001 Harris DS, Wolkowitz OM, Reus VI. Movement disorder, memory, psychiatric symproms and serum DHEA levels in schizophrenic and schizoaffective disorders. World Journal of Biological Psychiatry 2001;2(2):99-102.
39. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
40. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Cochrane Database of Systematic Reviews 2005, Issue 3.
41. Huber 2005 Huber TJ, Tettenborn C, Leifke E, Emrich HM. Sex hormones in psychotic men. Psychoneuroendocrinology 2005;30(1): 111-4.
42. Joy 2002 Joy CB, Admas CE, Lawrie SM. Haloperidol versus placebo in schizophrenia (Cochrane review). Cochrane Database of Systematic Reviews 2002, Issue 3.
43. Kay 1987 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
44. Kennedy 2002 Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical anipsychotic medication for schizophrenia (Cochrane review). Cochrane Database of Systematic Reviews 2002, Issue 3.
45. Leucht 2005a Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
46. Leucht 2005b Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
47. Lingjaerde 1987 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 1987;76(334):100.
48. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
49. Moher 2001 Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001;357:1191-4.
50. Mota Neto 2002 Mota Neto JIS, Lima MS, Soares BGO. Amisulpride for schizophrenia (Cochrane review). Cochrane Database of Systematic Reviews 2002, Issue 3.
51. Overall 1962 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
52. Ritsner 2005 Ritsner M, Gibel A, Maayan R, Ratner Y, Ram E, Biadsy H, Modai I, Weizman A. Cortisol/DHEA ratio and response to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 2005;30(10): 1913-22.
53. Rivaz-Vasquez 2003 Rivaz-Vasquez RA. Aripiprazole: a novel antipsychotic with novel prporties. Professional psychology:reserach and practice 2003;34(1):18-21.
54. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence for Bias:dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
55. Silver 2005 Silver H, Knoll G, Isakov V, Goodman C, Finkelstein Y. Blood DHEA concentrations correlate with cognitive function in chronic schizophrenic patients: a pilot study. Journal of Psychiatric Research 2005;39(6):569-75.
56. Strous 2003 Strous RD, Mayaan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive and anxiety symtoms in schizophrenia. Archives of General Psychiatry 2003;60(2):133-41.
57. Taherianfard 2005 Taherianfard M, Shariaty M. Evaluation of steroid hormones in schizophrenic patients. Indian Journal of Medical Science 2004;58(1):3-9.
58. Thornley 2002 Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane review). Cochrane Database of Systematic Reviews 2002, Issue 3.
59. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
60. Wahlbeck 2001 Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates randomized antipsychotic drug trials. Psychopharmacology 2001;155:230-3.